Ionis Pharmaceuticals (IONS) Set to Post Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) is anticipated to announce its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($1.22) per share and revenue of $181.56 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 10:30 AM ET.

Ionis Pharmaceuticals Price Performance

Shares of IONS stock opened at $43.52 on Monday. The stock’s 50 day simple moving average is $49.02 and its 200 day simple moving average is $66.82. The company has a debt-to-equity ratio of 3.07, a quick ratio of 7.73 and a current ratio of 7.89. Ionis Pharmaceuticals has a twelve month low of $42.08 and a twelve month high of $86.74. The company has a market capitalization of $7.23 billion, a price-to-earnings ratio of -12.58 and a beta of 0.43.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on IONS shares. HC Wainwright reiterated a “buy” rating on shares of Ionis Pharmaceuticals in a report on Thursday, October 22nd. Morgan Stanley reduced their price objective on shares of Ionis Pharmaceuticals from $110.00 to $104.00 and set an “overweight” rating for the company in a research note on Tuesday, September 8th. Raymond James Financial set a $79.00 price objective on shares of Ionis Pharmaceuticals in a report on Tuesday, October 20th. UBS Group started coverage on shares of Ionis Pharmaceuticals in a research note on Thursday, October 15th. They issued a “buy” rating and a $88.00 target price on the stock. Finally, Oppenheimer reiterated an “outperform” rating and issued a $85.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday, September 24th. Nineteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Ionis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $89.48.

Insider Activity at Ionis Pharmaceuticals

In related news, EVP Shannon Devers sold 1,357 shares of the business’s stock in a transaction on Friday, October 16th. The stock was sold at an average price of $43.54, for a total value of $59,083.78. Following the sale, the executive vice president owned 17,811 shares of the company’s stock, valued at $775,490.94. The trade was a 7.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 1.81% of the stock is owned by company insiders.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing medicines using antisense technology. Its platform is designed to selectively target RNA and regulate the production of disease-related proteins. The company develops therapies for neurological, cardiovascular and metabolic, and rare diseases.

Ionis has developed and commercialized medicines both independently and through collaborations with larger pharmaceutical companies. Its marketed or partnered products include Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) and Wainua (eplontersen) for hereditary transthyretin amyloidosis, and Tryngolza (olezarsen) for familial chylomicronemia syndrome.